Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
30 07 2021
30 07 2021
Historique:
received:
21
05
2021
accepted:
09
07
2021
revised:
05
07
2021
entrez:
31
7
2021
pubmed:
1
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients underwent extended interval (10-12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific antibody responses were detectable in 34% of patients with CLL after one vaccine (n = 267) compared to 94% in healthy donors with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n = 55), compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine. This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster vaccines.
Identifiants
pubmed: 34330895
doi: 10.1038/s41408-021-00528-x
pii: 10.1038/s41408-021-00528-x
pmc: PMC8323747
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2021. The Author(s).
Références
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
J Immunol Methods. 2021 Jul;494:113046
pubmed: 33775672
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Elife. 2021 Sep 29;10:
pubmed: 34586068
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Clin Immunol. 2004 Apr;111(1):93-7
pubmed: 15093556
Br J Haematol. 2018 Sep;182(5):712-714
pubmed: 28737280
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Blood Adv. 2019 Jul 23;3(14):2188-2198
pubmed: 31324639
Haematologica. 2017 Oct;102(10):e397-e399
pubmed: 28659336
Semin Immunol. 2018 Dec;40:83-94
pubmed: 30501873
Br J Haematol. 2017 Aug;178(3):394-402
pubmed: 28580636
Baillieres Clin Haematol. 1987 Jun;1(2):449-91
pubmed: 3322445
Blood. 2021 Jan 14;137(2):185-189
pubmed: 33259596
Nat Mater. 2020 Aug;19(8):810-812
pubmed: 32704139
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Leuk Res. 2020 Jun;93:106366
pubmed: 32388230
Leukemia. 2021 Mar;35(3):737-746
pubmed: 32555297